{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T04:59:57Z","timestamp":1770267597503,"version":"3.49.0"},"reference-count":48,"publisher":"Academy of Managed Care Pharmacy","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMCP"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.18553\/jmcp.2025.25169","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T12:10:23Z","timestamp":1764763823000},"page":"186-200","source":"Crossref","is-referenced-by-count":0,"title":["Real-world overall survival comparison between first-line Bruton tyrosine kinase inhibitors in treating chronic lymphocytic leukemia\/small lymphocytic lymphoma: An analysis of Veterans Health Administration data"],"prefix":"10.18553","volume":"32","author":[{"given":"Lindsey","family":"Fitzgerald","sequence":"first","affiliation":[{"name":"Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City"},{"name":"George E. Wahlen Veterans Affairs Medical Center, Salt Lake City, UT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabyasachi","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, a Johnson & Johnson Company, Horsham, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wasiulla","family":"Khan","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, a Johnson & Johnson Company, Horsham, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Bokun","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, a Johnson & Johnson Company, Horsham, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Lax","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Mu","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin E.","family":"Cook","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyi","family":"Chen","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"Chen","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Wu","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yilu","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Management, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA"},{"name":"Southeast Louisiana Veterans Health Care System, New Orleans"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lizheng","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Management, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA"},{"name":"Southeast Louisiana Veterans Health Care System, New Orleans"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaina P.","family":"Qureshi","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, a Johnson & Johnson Company, Horsham, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solomon A.","family":"Graf","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Washington School of Medicine, Seattle"},{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA"},{"name":"Hospital and Specialty Medicine, Veterans Affairs Puget Sound Health Care System, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7818","reference":[{"key":"r1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000412"},{"key":"r2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.686768"},{"key":"r3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21590"},{"key":"r4","unstructured":"National Cancer Institute. Cancer Stat Facts: NHL \u2014 Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (CLL\/SLL). Accessed December 24, 2024. https:\/\/seer.cancer.gov\/statfacts\/html\/cllsll.html"},{"key":"r5","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0131-2"},{"key":"r6","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01054-w"},{"key":"r7","unstructured":"IMBRUVICA (ibrutinib). Prescribing information. Janssen Biotech, Inc; 2020."},{"key":"r8","first-page":"66","volume":"8","author":"Raedler LA","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"r9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"r10","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0276-9"},{"key":"r11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30788-5"},{"key":"r12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817073"},{"key":"r13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812836"},{"key":"r14","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.74"},{"key":"r15","unstructured":"US Food and Drug Administration. Project Orbis: FDA approves acalabrutinib for CLL and SLL. Accessed November 28, 2023. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/project-orbis-fda-approves-acalabrutinib-cll-and-sll"},{"key":"r16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30262-2"},{"key":"r17","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011307"},{"key":"r18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01210"},{"key":"r19","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018818"},{"key":"r20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00293-5"},{"key":"r21","unstructured":"US Food and Drug Administration. FDA approves zanubrutinib for chronic lymphocytic leukemia or small lymphocytic lymphoma. Accessed November 28, 2023. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-zanubrutinib-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma"},{"key":"r22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211582"},{"key":"r23","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2020.20095"},{"key":"r24","unstructured":"US Department of Veterans Affairs. Chronic B-cell Leukemias and Agent Orange. Accessed November 28, 2023. https:\/\/www.publichealth.va.gov\/exposures\/agentorange\/conditions\/bcell-leukemia.asp"},{"key":"r25","unstructured":"American Cancer Society. Chronic Lymphocytic Leukemia Causes, Risk Factors, and Prevention. Accessed November 28, 2023. https:\/\/www.cancer.org\/content\/dam\/CRC\/PDF\/Public\/8680.00.pdf"},{"key":"r26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-201206"},{"key":"r27","doi-asserted-by":"publisher","DOI":"10.1186\/1478-7954-4-2"},{"key":"r28","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0436"},{"key":"r29","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfy026"},{"key":"r30","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007938"},{"key":"r31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-152167"},{"key":"r32","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"r33","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-19425-7_4"},{"issue":"2","key":"r34","first-page":"172","volume":"5","author":"Babalola BT","year":"2020","journal-title":"J Biostat Epidemiol"},{"key":"r35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02265"},{"key":"r36","unstructured":"Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65\u00a0Years or Older With Treatment-naive CLL or SLL. Accessed December 25, 2024. https:\/\/clinicaltrials.gov\/study\/NCT01722487"},{"key":"r37","unstructured":"A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL (SEQUOIA). Accessed December 25, 2024. https:\/\/www.clinicaltrials.gov\/study\/NCT03336333"},{"key":"r38","unstructured":"Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment na\u00efve CLL (ElevateTN). Accessed December 25, 2024, https:\/\/clinicaltrials.gov\/study\/NCT02475681"},{"key":"r39","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.10136"},{"key":"r40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsb1609216"},{"key":"r41","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.07.004"},{"key":"r42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-12-737346"},{"key":"r43","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S417180"},{"key":"r44","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162797"},{"key":"r45","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2012.18.7.527"},{"key":"r46","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-181774"},{"key":"r47","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2998"},{"key":"r48","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2021.03.005"}],"container-title":["Journal of Managed Care & Specialty Pharmacy"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T15:32:07Z","timestamp":1770219127000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jmcp.org\/doi\/10.18553\/jmcp.2025.25169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.18553\/jmcp.2025.25169"],"URL":"https:\/\/doi.org\/10.18553\/jmcp.2025.25169","relation":{},"ISSN":["2376-0540","2376-1032"],"issn-type":[{"value":"2376-0540","type":"print"},{"value":"2376-1032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}